14.59MMarket Cap
LossP/E TTM
Cyclerion Therapeutics Inc
Key Figures
3.480Open
3.595High
15.71KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.37%Turnover Ratio
3.500Prev. Close
3.361Low
49.79KTurnover
LossP/E Static
2.15P/B
0.00%Div Yield TTM
-57.50%ROA
8.48052wk High
0.65Volume Ratio
-3.06MNet Profit
4.24MShares
-1.3055EPS TTM
1.80Beta
-67.77%ROE
1.02752wk Low
6.70%Amplitude
100.00%Gross Margin
14.59MMarket Cap
0.35Reward/Risk
5.76%Risk Rate
Currency: USD Updated: 2026-07-31 Key Insights
Cyclerion Therapeutics Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 182 out of 385 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as , with the highest price target at 8.00.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Cyclerion Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Cyclerion Therapeutics Inc Highlights
StrengthsRisks
Cyclerion Therapeutics Inc News
More news coming soon, stay tuned...
Earnings Forecast
Strong Buy
Buy
Hold
Sell
Strong Sell
Ionis Pharmaceuticals Inc
IONS
25
Indicators
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Cyclerion Therapeutics Inc Info
Cyclerion Therapeutics, Inc. is a biopharmaceutical company dedicated to identifying, developing, and delivering therapies for central nervous system (CNS) diseases. The Company is focused on building a pipeline with therapeutics to treat certain neuropsychiatric diseases. It is focused on an individualized therapy for treatment-resistant depression (TRD) - a condition with significant unmet medical need. Its assets include Olinciguat and Praliciguat. The Company has entered into an exclusive license option agreement for its vascular soluble guanylate cyclase (sGC) stimulator, olinciguat. Praliciguat is an oral, once-daily, systemic sGC stimulator that is licensed to Akeibia Therapeutics, Inc and is being advanced in rare kidney disease.
Ticker SymbolCYCN
CompanyCyclerion Therapeutics Inc
CEOGraul (Regina M)
Websitehttps://www.cyclerion.com/
Shareholders
FAQs
What is the current price of Cyclerion Therapeutics Inc (CYCN)?
The current price of Cyclerion Therapeutics Inc (CYCN) is 3.52.
What is the symbol of Cyclerion Therapeutics Inc?
The ticker symbol of Cyclerion Therapeutics Inc is CYCN.
What is the 52-week high of Cyclerion Therapeutics Inc?
The 52-week high of Cyclerion Therapeutics Inc is 8.48.
What is the 52-week low of Cyclerion Therapeutics Inc?
The 52-week low of Cyclerion Therapeutics Inc is 1.03.
What is the market capitalization of Cyclerion Therapeutics Inc?
The market capitalization of Cyclerion Therapeutics Inc is 14.95M.
What is the Earnings Per Share (EPS TTM) of Cyclerion Therapeutics Inc (CYCN)?
The Earnings Per Share (EPS TTM) of Cyclerion Therapeutics Inc (CYCN) is -1.11.
